There are no approved treatments for nonrelapsing secondary progressive multiple sclerosis. In a phase 3, double-blind, placebo-controlled, event-driven trial, we randomly assigned participants ...

New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.

Stem cells from donated placentas appear safe and may help ease secondary progressive MS, a small open-label Phase 1 clinical ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

Cognitive symptoms, mood disorders, and fatigue manifest differently in relapsing-remitting vs. progressive forms of MS, a ...

The following is a summary of “Secondary progression activity monitoring in MS despite an early highly active treatment the ...

The NHS has warned about potential symptoms of an incurable condition that profoundly affects the central nervous system.

SAN DIEGO — Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients with non-relapsing secondary progressive multiple sclerosis ...

HERCULES evaluated 1,131 non-relapsing secondary progressive MS patients with a median baseline EDSS of 6.0 who were randomized to tolebrutinib or placebo. In HERCULES, tolebrutinib slowed ...